Induction of Protective Immune Responses Against Schistosomiasis Using Functionally Active Cysteine Peptidases

Overview

Journal Front Genet

Date 2014 May 22

PMID 24847355

Citations 23

Authors

Rashika El Ridi

Hatem Tallima

John P Dalton

Sheila Donnelly

Affiliations

Soon will be listed here.

Abstract

Each year schistosomiasis afflicts up to 600 million people in 74 tropical and sub-tropical countries, predominantly in the developing world. Yet we depend on a single drug, praziquantel, for its treatment and control. There is no vaccine available but one is urgently needed especially since praziquantel-resistant parasites are likely to emerge at some time in the future. The disease is caused by several worm species of the genus Schistosoma. These express several classes of papain-like cysteine peptidases, cathepsins B and L, in various tissues but particularly in their gastrodermis where they employ them as digestive enzymes. We have shown that sub-cutaneous injection of recombinant and functionally active Schistosoma mansoni cathepsin B1 (SmCB1), or a cathepsin L from a related parasite Fasciola hepatica (FhCL1), elicits highly significant protection (up to 73%) against an experimental challenge worm infection in murine models of schistosomiasis. The immune modulating properties of this subcutaneous injection can boost protection levels (up to 83%) when combined with other S. mansoni vaccine candidates, glyceraldehyde 3-phosphate dehydrogenase (SG3PDH) and peroxiredoxin (PRX-MAP). Here, we discuss these data in the context of the parasite's biology and development, and provide putative mechanism by which the native-like cysteine peptidase induce protective immune responses.

Citing Articles

Approaches of Inducing Tolerance to Murine Schistosomiasis mansoni applying Biomphalaria and Bulinus Proteins.

Mossalem H, Nasr S, Fahmy A, Atta S, Abuelenain G Acta Parasitol. 2025; 70(1):41.

PMID: 39853639 PMC: 11761983. DOI: 10.1007/s11686-025-00988-2.

Evaluation of the prophylactic and therapeutic efficacies of mucus and tissue nucleoproteins extracted from snails on schistosomiasis .

Nafie E, Abou-Gamra M, Mossalem H, Sarhan R, Hammam O, Nasr S J Parasit Dis. 2024; 48(3):551-569.

PMID: 39145357 PMC: 11319553. DOI: 10.1007/s12639-024-01692-0.

Comparative membrane proteomic analysis of Tritrichomonas foetus isolates.

Rivero M, Alonso A, Abdala M, Luque M, Carranza P, Coceres V Sci Rep. 2024; 14(1):17033.

PMID: 39043862 PMC: 11266394. DOI: 10.1038/s41598-024-67827-8.

Antigenic epitope targets of rhesus macaques self-curing from infection.

Vance G, Khouri M, Neto A, James S, Leite L, Farias L Front Immunol. 2024; 14:1269336.

PMID: 38464672 PMC: 10921417. DOI: 10.3389/fimmu.2023.1269336.

Schistosoma mansoni vaccine candidates identified by unbiased phage display screening in self-cured rhesus macaques.

Woellner-Santos D, Tahira A, Malvezzi J, Mesel V, Morales-Vicente D, Trentini M NPJ Vaccines. 2024; 9(1):5.

PMID: 38177171 PMC: 10767053. DOI: 10.1038/s41541-023-00803-x.

References

Roche N, Chinet T, Huchon G . Allergic and nonallergic interactions between house dust mite allergens and airway mucosa. Eur Respir J. 1997; 10(3):719-26. View

Eberl M, Langermans J, Frost P, Vervenne R, van Dam G, Deelder A . Cellular and humoral immune responses and protection against schistosomes induced by a radiation-attenuated vaccine in chimpanzees. Infect Immun. 2001; 69(9):5352-62. PMC: 98645. DOI: 10.1128/IAI.69.9.5352-5362.2001. View

Black C, Muok E, Mwinzi P, Carter J, Karanja D, Evan Secor W . Increases in levels of schistosome-specific immunoglobulin E and CD23(+) B cells in a cohort of Kenyan children undergoing repeated treatment and reinfection with Schistosoma mansoni. J Infect Dis. 2010; 202(3):399-405. PMC: 2897938. DOI: 10.1086/653828. View

McManus D, Loukas A . Current status of vaccines for schistosomiasis. Clin Microbiol Rev. 2008; 21(1):225-42. PMC: 2223839. DOI: 10.1128/CMR.00046-07. View

Day S, Dalton J, Clough K, Leonardo L, Tiu W, Brindley P . Characterization and cloning of the cathepsin L proteinases of Schistosoma japonicum. Biochem Biophys Res Commun. 1995; 217(1):1-9. DOI: 10.1006/bbrc.1995.2737. View

Wasilewski M, Lim K, Phillips J, McKerrow J . Cysteine protease inhibitors block schistosome hemoglobin degradation in vitro and decrease worm burden and egg production in vivo. Mol Biochem Parasitol. 1996; 81(2):179-89. DOI: 10.1016/0166-6851(96)02703-x. View

Stack C, Dalton J, Robinson M . The phylogeny, structure and function of trematode cysteine proteases, with particular emphasis on the Fasciola hepatica cathepsin L family. Adv Exp Med Biol. 2011; 712:116-35. DOI: 10.1007/978-1-4419-8414-2_8. View

Nhu Q, Shirey K, Teijaro J, Farber D, Netzel-Arnett S, Antalis T . Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal Immunol. 2009; 3(1):29-39. PMC: 2851245. DOI: 10.1038/mi.2009.120. View

Mutapi F, Ndhlovu P, Hagan P, Spicer J, Mduluza T, Turner C . Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection. J Infect Dis. 1998; 178(1):289-93. DOI: 10.1086/517456. View

10.

Pollock K, McNeil K, Mottram J, Lyons R, Brewer J, Scott P . The Leishmania mexicana cysteine protease, CPB2.8, induces potent Th2 responses. J Immunol. 2003; 170(4):1746-53. DOI: 10.4049/jimmunol.170.4.1746. View

11.

Chapman M, Wunschmann S, Pomes A . Proteases as Th2 adjuvants. Curr Allergy Asthma Rep. 2007; 7(5):363-7. DOI: 10.1007/s11882-007-0055-6. View

12.

Anderson S, Shires V, Wilson R, Mountford A . Formation of multinucleated giant cells in the mouse lung is promoted in the absence of interleukin-12. Am J Respir Cell Mol Biol. 1999; 20(3):371-8. DOI: 10.1165/ajrcmb.20.3.3317. View

13.

Caffrey C, Rheinberg C, Mone H, Jourdane J, Li Y, Ruppel A . Schistosoma japonicum, S. mansoni, S. haematobium, S. intercalatum, and S. rodhaini: cysteine-class cathepsin activities in the vomitus of adult worms. Parasitol Res. 1997; 83(1):37-41. DOI: 10.1007/s004360050204. View

14.

Smythies L, Pemberton R, Coulson P, Mountford A, Wilson R . T cell-derived cytokines associated with pulmonary immune mechanisms in mice vaccinated with irradiated cercariae of Schistosoma mansoni. J Immunol. 1992; 148(5):1512-8. View

15.

Dvorak J, Mashiyama S, Braschi S, Sajid M, Knudsen G, Hansell E . Differential use of protease families for invasion by schistosome cercariae. Biochimie. 2007; 90(2):345-58. DOI: 10.1016/j.biochi.2007.08.013. View

16.

Curwen R, Ashton P, Sundaralingam S, Wilson R . Identification of novel proteases and immunomodulators in the secretions of schistosome cercariae that facilitate host entry. Mol Cell Proteomics. 2006; 5(5):835-44. DOI: 10.1074/mcp.M500313-MCP200. View

17.

Walter K, Fulford A, McBeath R, Joseph S, Jones F, Kariuki H . Increased human IgE induced by killing Schistosoma mansoni in vivo is associated with pretreatment Th2 cytokine responsiveness to worm antigens. J Immunol. 2006; 177(8):5490-8. DOI: 10.4049/jimmunol.177.8.5490. View

18.

Harrison R, Doenhoff M . Retarded development of Schistosoma mansoni in immunosuppressed mice. Parasitology. 1983; 86 (Pt 3):429-38. DOI: 10.1017/s0031182000050629. View

19.

Riner D, Ferragine C, Maynard S, Davies S . Regulation of innate responses during pre-patent schistosome infection provides an immune environment permissive for parasite development. PLoS Pathog. 2013; 9(10):e1003708. PMC: 3795041. DOI: 10.1371/journal.ppat.1003708. View

20.

Delcroix M, Sajid M, Caffrey C, Lim K, Dvorak J, Hsieh I . A multienzyme network functions in intestinal protein digestion by a platyhelminth parasite. J Biol Chem. 2006; 281(51):39316-29. DOI: 10.1074/jbc.M607128200. View